Showing 7721-7740 of 8668 for: Cochrane Systematic Reviews Back
- Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants
Cochrane Systematic Reviews, 31-Jan-2017
Cochrane systematic reviews show that systemic postnatal corticosteroids reduce the risk of bronchopulmonary dysplasia (BPD) in preterm infants. However, corticosteroids have also been associated with an increased risk of neurodevelopmental impairment. It
- Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease
Cochrane Systematic Reviews, 28-Aug-2014
Acute exacerbations of chronic obstructive pulmonary disease (COPD) are a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity and quality of life. The most common causes are infective,
- Systemic corticosteroids for acute gout
Cochrane Systematic Reviews, 23-Apr-2008
Gout is one of the most frequently occurring rheumatic diseases, worldwide. Given the well-known drawbacks of the regular treatments for acute gout (non-steroidal anti-inflammatory drugs (NSAIDs), colchicine), systemic corticosteroids might be safe altern
- Systemic corticosteroids for acute otitis media in children
Cochrane Systematic Reviews, 15-Mar-2018
Acute otitis media (AOM) is a common acute infection in children. Pain is its most prominent and distressing symptom. Antibiotics are commonly prescribed for AOM, although they have only a modest effect in reducing pain at two to three days. There is insu
- Systemic corticosteroids for acute sinusitis
Cochrane Systematic Reviews, 25-Mar-2014
Acute sinusitis is the inflammation and swelling of the nasal and paranasal mucous membranes and is a common reason for patients to seek primary care consultations. The related impairment of daily functioning and quality of life is attributable to symptom
- Systemic corticosteroids for the management of cancer‐related breathlessness (dyspnoea) in adults
Cochrane Systematic Reviews, 20-Feb-2019
Dyspnoea is a common symptom in advanced cancer, with a prevalence of up to 70% among patients at end of life. The cause of dyspnoea is often multifactorial, and may cause considerable psychological distress and suffering. Dyspnoea is often undertreated a
- Systemic corticosteroids for the treatment of COVID‐19
Cochrane Systematic Reviews, 16-Aug-2021
Systemic corticosteroids are used to treat people with COVID-19 because they counter hyper-inflammation. Existing evidence syntheses suggest a slight benefit on mortality. So far, systemic corticosteroids are one of the few treatment options for COVID-19.
- Systemic interventions for recurrent aphthous stomatitis (mouth ulcers)
Cochrane Systematic Reviews, 13-Aug-2012
Recurrent aphthous stomatitis (RAS) is the most frequent form of oral ulceration, characterised by recurrent oral mucosal ulceration in an otherwise healthy individual. At its worst RAS can cause significant difficulties in eating and drinking. Treatment
- Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years
Cochrane Systematic Reviews, 21-Oct-2020
Atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) are severe and potentially sight-threatening allergic eye diseases characterised by chronic inflammation of the ocular surface. Both topical and systemic treatments are used. This Coc
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
Cochrane Systematic Reviews, 19-Apr-2021
Psoriasis is an immune-mediated disease for which some people have a genetic predisposition. The condition manifests in inflammatory effects on either the skin or joints, or both, and it has a major impact on quality of life. Although there is currently n
- Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults
Cochrane Systematic Reviews, 23-Jan-2008
Postoperative adynamic bowel atony interferes with recovery following abdominal surgery. Prokinetic pharmacologic drugs are widely used to accelerate postoperative recovery.
- Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
Cochrane Systematic Reviews, 5-Sep-2014
Neovascular age-related macular degeneration (AMD) is the leading cause of legal blindness in elderly populations of industrialised countries. Bevacizumab (Avastin®) and ranibizumab (Lucentis®) are targeted biological drugs (a monoclonal antibody) that in
- Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast cancer
Cochrane Systematic Reviews, 10-Jan-2022
Adjuvant aromatase inhibitors (AI) improve survival compared to tamoxifen in postmenopausal women with hormone receptor-positive stage I to III breast cancer. In approximately half of these women, AI are associated with aromatase inhibitor-induced musculo
- Systemic therapy for treating locoregional recurrence in women with breast cancer
Cochrane Systematic Reviews, 23-Oct-2001
Between 10% and 35% of women with operable breast cancer will experience an isolated locoregional recurrence following their primary treatment. There is currently no good evidence that adjuvant systemic treatment is effective in this situation and there i
- Systemic treatment for blepharokeratoconjunctivitis in children
Cochrane Systematic Reviews, 26-May-2016
Blepharokeratoconjunctivitis (BKC) is a type of inflammation of the surface of the eye and eyelids which can affect children and adults. BKC involves changes of the eyelids, dysfunction of the meibomian glands, and inflammation of the conjunctiva and corn
- Systemic treatments for eczema: a network meta‐analysis
Cochrane Systematic Reviews, 14-Sep-2020
Eczema is a common and chronic, relapsing, inflammatory skin disorder. It seriously impacts quality of life and economic outcomes, especially for those with moderate to severe eczema. Various treatments allow sustained control of the disease; however, the
- Systemic treatments for metastatic cutaneous melanoma
Cochrane Systematic Reviews, 7-Feb-2018
Systemic therapies for metastatic cutaneous melanoma, the most aggressive of all skin cancers, remain disappointing. Few lasting remissions are achieved and the therapeutic aim remains one of palliation.
- Systemic treatments for metastatic cutaneous melanoma
Cochrane Systematic Reviews, 6-Feb-2018
The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is generally poor. Recently, new classes of drugs (e.g. immune checkpoint inhibitors and small-molecule targeted drugs) have significantly improved patient prognosis, which has dra
- Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters
Cochrane Systematic Reviews, 10-Sep-2013
Venous thrombo-embolic events (VTEs) occur in 2.2% to 14% of paediatric cancer patients and cause significant morbidity and mortality. The malignant disease itself, the cancer treatment and the presence of central venous catheters (CVCs) increase the risk
- Systems for routine surveillance in people with diabetes mellitus
Cochrane Systematic Reviews, 10-Nov-2008
There is wide variation in the extent of general practice involvement in diabetes care.
